1. Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study. (February 2017) Authors: Nanda, R.; Specht, J.; Dees, E.C.; Berger, R.; Gupta, S.; Geva, R.; Pusztai, L.; Pathiraja, K.; Ray, A.; Karantza, V.; Buisseret, L. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor. (October 2020) Authors: Kizilbash, S.H.; El-Khoueiry, A.; Lerner, R.E.; Ma, P.C.; Almubarak, M.; Mody, K.; Burkard, M.E.; Guarino, M.; Jenab-Wolcott, J.; Sankar, N.; Choy, G.; Espiritu, L.; Zhang, X.; Luria, A.; Benedetti, F.; Dees, E.C. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗